MedPath

Congenital Cytomegalovirus: Prevalence in Buenos Aires City (cCMV Prevalence)

Not yet recruiting
Conditions
Congenital Cytomegalovirus
Registration Number
NCT05630898
Lead Sponsor
Hospital de Niños R. Gutierrez de Buenos Aires
Brief Summary

The goal of this observational study is to recognise the prevalnce of congenital cytomegalovirus (cCMV) and to follow up positive babies until 12 months The main questions it aims to answer are: pevalence of cCMV, cCMV clinicals outcomes during the first year of life.

Participants will be screened with a salive swab for CMV DNA. Babies with positive results will be follow up for one year.

Detailed Description

Cytomegalovirus (CMV) is a frequent cause of congenital infection and a leading nongenetic cause of sensorineural hearing loss. In most infants with congenital CMV infection, clinical abnormalities do not manifest at birth; rather, the infection is asymptomatic. However, sensorineural hearing loss eventually develops in approximately 10 to 15% of CMV positive children.

The prevalence of congenital cytomegalovirus has been reported as 0·2% to 2·0% (average of 0·64%). There is not any publication of the prevalence of cCMV in Buenos Aires City. We aim the study to find the prevalence in this population Screening of newborns for CMV infection permit early identification of at-risk congenitally infected infants for purposes of targeted monitoring and intervention during critical stages of speech and language development.

Testing saliva via DNA detection of the virus through polymerase chain reaction testing (PCR) or rapid culture is shown to have a high sensitivity (\>97%) and specificity (99%) for detecting congenital CMV infection.

Our objective is to describe the prevalence of cCMV using saliva specimens for PCR detection.

Secondary objectives includes describing prevalence of neurosensorial hearing loss and visual impairments during 1 year follow up.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
3000
Inclusion Criteria
  • Newborns between 1 and 21 days
  • informed consent
Exclusion Criteria
  • Lethal malformation

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
prevalence of cCMV5 months

newborns positive for CMV

Secondary Outcome Measures
NameTimeMethod
incidence of neurosensorial hearing loss during the 1° year of life1 year

fail Hearing test

incidence of visual impairments detected during the 1° year of life1 year

anormal eye exam

Trial Locations

Locations (3)

Hospital Materno Infantil Ramón Sardá

🇦🇷

Ciudad Autonoma De Buenos Aires, Buenos Aires, Argentina

Clinica y maternidad Suizo Argentina

🇦🇷

Ciudad Autonoma De Buenos Aires, Buenos Aires, Argentina

Hospital de Niños Ricardo Gutiérrez

🇦🇷

Ciudad Autonoma De Buenos Aires, Buenos Aires, Argentina

© Copyright 2025. All Rights Reserved by MedPath